Table 1.
Means and frequencies of participants’ characteristics by HSF1 status from NHS (1976–1996)
| Characteristic | No HSF1 | Low HSF1 | High HSF1 |
| n (%) | 404 (21.9) | 882 (47.9) | 555 (30.2) |
| Age at diagnosis, mean (n), y | 57.8 (404) | 56.8 (882) | 57.6 (555) |
| Menopausal status at diagnosis, n* (%) | |||
| Premenopausal | 74 (18.6) | 219 (25.3) | 109 (20.2) |
| Postmenopausal | 325 (81.5) | 648 (74.7) | 432 (79.9) |
| ER status, n* (%) | |||
| Positive | 334 (82.7) | 702 (79.4) | 412 (71.2) |
| Negative | 70 (17.3) | 182 (20.6) | 167 (28.8) |
| HER2 status, n* (%) | |||
| Positive | 23 (5.8) | 95 (10.7) | 81 (14.1) |
| Negative | 375 (94.2) | 794 (89.3) | 494 (85.9) |
| Triple-negative tumors, n* (%) | |||
| Yes | 49 (12.2) | 122 (13.7) | 108 (18.7) |
| No | 353 (87.8) | 766 (86.3) | 471 (81.4) |
| Nodal involvement, n (%) | |||
| None | 290 (71.8) | 590 (66.9) | 324 (58.4) |
| 1–3 | 72 (17.8) | 166 (18.8) | 134 (24.1) |
| 4–9 | 26 (6.4) | 78 (8.8) | 55 (9.9) |
| ≥10 | 16 (4.0) | 48 (5.4) | 42 (7.6) |
| Tumor size, n (%) | |||
| ≤2 cm | 301 (74.5) | 589 (66.8) | 295 (53.2) |
| >2 cm | 103 (25.5) | 293 (33.2) | 260 (46.9) |
| Histological grade, n* (%) | |||
| I (low) | 143 (35.8) | 159 (18.2) | 51 (9.3) |
| II (intermediate) | 199 (49.8) | 543 (62.1) | 284 (51.7) |
| III (high) | 58 (14.5) | 173 (19.8) | 214 (39.0) |
| Stage,†n (%) | |||
| I | 239 (59.2) | 452 (51.3) | 217 (39.1) |
| II | 114 (28.2) | 283 (32.1) | 225 (40.5) |
| III | 51 (12.6) | 147 (16.7) | 113 (20.4) |
| Chemotherapy, n* (%) | |||
| Yes | 101 (33.2) | 263 (41.9) | 217 (50.6) |
| No | 203 (66.8) | 365 (58.1) | 212 (49.4) |
| Hormone treatment, n* (%) | |||
| Yes | 207 (68.8) | 415 (66.3) | 280 (66.0) |
| No | 94 (31.2) | 211 (33.7) | 144 (34.0) |
| Radiation treatment, n* (%) | |||
| Yes | 136 (44.4) | 275 (43.7) | 185 (43.3) |
| No | 170 (55.6) | 354 (56.3) | 242 (56.7) |
*n for these characteristics does not add up to total studied (n = 1,841) because of missing information.
†Stage I: tumor size ≤2 cm and no nodal involvement; stage II: tumor size ≤2 cm and 1–3 nodes, 2–4 cm and 0–3 nodes, or 4+ cm and 0 nodes; stage III: tumor size ≤2 cm and 4+ nodes, 2–4 cm and 4+ nodes, or >4 cm and 1+ nodes.